A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19

PHASE4UnknownINTERVENTIONAL
Enrollment

576

Participants

Timeline

Start Date

March 17, 2021

Primary Completion Date

June 7, 2021

Study Completion Date

December 31, 2021

Conditions
Covid19
Interventions
BIOLOGICAL

Bamlanivimab

700 mg/20mL IV over at least one hour OD

OTHER

Standard of Care

Standard of care includes primary care and specialist care as indicated by the patient's primary care provider

Trial Locations (1)

Unknown

Fraser Health Authority, Fraser Health Region

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Fraser Health Authrority Department of Evaluation and Research Services

UNKNOWN

collaborator

Surrey Memorial Hospital Clinical Research Unit

UNKNOWN

collaborator

Centre for Health Evaluation and Outcome Sciences

UNKNOWN

collaborator

Surrey Hospital Foundation

UNKNOWN

collaborator

BC Support Unit

OTHER

collaborator

University of British Columbia

OTHER

collaborator

Ministry of Health, British Columbia

OTHER_GOV

collaborator

Clinical Trials BC (part of the BC Academic Health Science Network)

UNKNOWN

lead

Fraser Health

OTHER

NCT04796402 - A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19 | Biotech Hunter | Biotech Hunter